13Indexed trials
drug · Product Intelligence
Olanzapine
Pipeline Intelligence
Olanzapine: 13 indexed trials, 10 sponsors; 0 linked Orange Book patents and 7 FDA-linked events where matched.
10Sponsors
0Orange Book patent links
7FDA-linked events
Development evidence
NCT00035321Eli Lilly and Company · depressionPHASE3
NCT00044655Icahn School of Medicine at Mount Sinai · schizophreniaPHASE4
NCT00190749Eli Lilly and Company · schizophreniaPHASE4
NCT00222495University of Minnesota · schizophreniaNA
NCT00273624University Hospital Freiburg · depressionPHASE3
NCT00320489Eli Lilly and Company · schizophreniaPHASE3
NCT00510146Eli Lilly and Company · depressionPHASE3
NCT00615433Sumitomo Pharma America, Inc. · schizophreniaPHASE3
NCT01057329Medical University of Vienna · adhdCOMPLETED
NCT01496183State University of New York at Buffalo · out_of_scopeNA
NCT02462473Janssen Research & Development, LLC · schizophreniaPHASE2
NCT04478838Centre for Addiction and Mental Health · schizophreniaPHASE4
NCT07565428Minerva Neurosciences · schizophreniaPHASE3
FDA / patent evidence
Orange Book match found; no listed patent relation was retained for this product match.
Regulatory context
FDA_APPROVALOLANZAPINE · 2016-08-30
FDA_APPROVALOLANZAPINE · 2015-10-20
FDA_APPROVALOLANZAPINE · 2015-04-29
FDA_APPROVALOLANZAPINE · 2014-05-15
FDA_APPROVALOLANZAPINE · 2012-09-12
FDA_APPROVALOLANZAPINE · 2012-04-23
FDA_APPROVALOLANZAPINE · 2012-04-23
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.